{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219424","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2026-05-12T20:10:18+00:00","discovered_at":"2026-05-12T20:11:00.300712+00:00","generated_at":"2026-05-12T21:07:38.707912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PepGen Q1 net loss $17.8M; cash $132.3M; 10 mg/kg DM1 cohort fully enrolled","bullets":["Net loss of $17.8M ($0.26 per share) vs $30.2M loss in Q1 2025; R&D spend down to $13.0M from $25.4M.","Cash, equivalents and marketable securities $132.3M; funding seen into 2H 2027.","FREEDOM2-DM1 5 mg/kg cohort showed favorable safety, splicing and vHOT trends; 10 mg/kg cohort fully enrolled with data expected 2H 2026.","FDA partial clinical hold on FREEDOM2 relates to preclinical studies; timing of ongoing trial not impacted.","13 patients enrolled in open-label extension at 5 mg/kg with no discontinuations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219424","json":"https://secwatch.observer/filing/0001193125-26-219424.json","markdown":"https://secwatch.observer/filing/0001193125-26-219424.md","text":"https://secwatch.observer/filing/0001193125-26-219424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/0001193125-26-219424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526219424/pepg-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:07:38.707912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}